Alpha-201-macro1

Alpha-201-macro1 is an investigational oncolytic viral immunotherapy developed by Candel Therapeutics. It is the first experimental agent from the enLIGHTEN Discovery Platform, which utilizes a herpes simplex virus (HSV)-based chassis engineered to deliver immunostimulatory gene payloads. The drug is designed to activate innate immune surveillance and modulate the tumor microenvironment, thereby enhancing anti-tumor immune responses, particularly in combination with immune checkpoint inhibitors. Its mechanism centers on targeting and interfering with the CD47/SIRPα pathway—a key axis involved in tumor cell evasion of macrophage-mediated phagocytosis—by delivering a novel gene payload locally within tumors. Preclinical data suggest that local delivery of this multimodal agent may offer therapeutic benefits while potentially reducing systemic toxicity associated with other CD47/SIRPα-targeted therapies[1][2].

Other names

Alpha-201-macro1Alpha201-macro1Alpha 201-macro1